{"version":"1.0","type":"rich","provider_name":"techandbusiness.org","provider_url":"https://techandbusiness.org","title":"FDA places Regenxbio's Hunter syndrome gene therapy on clinical hold","author_name":"techandbusiness.org · Policy","thumbnail_url":"https://etimg.etb2bimg.com/thumb/msid-133510617,imgsize-1132487,width-1200,height=627,overlay-etpharma,resizemode-75/news/pharma-industry/fda-places-clinical-hold-on-regenxbios-gene-therapy-for-hunter-syndrome.jpg","width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;\">techandbusiness.org · Policy</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/Oz5xB4p6t2DIsWmTNokNTf\" style=\"color:#fff;text-decoration:none;\">FDA places Regenxbio's Hunter syndrome gene therapy on clinical hold</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">The FDA has placed Regenxbio's experimental RGX-121 gene therapy for Hunter syndrome on clinical hold, Regenxbio said, after spinal scans found abnormalities in five study participants. The company sa...</p>\n    </blockquote>"}